The 2026 American Academy of Dermatology (AAD) Annual Meeting

A review of literature presented at AAD 2026 reveals an association between hijab wearing and unique hair and scalp disorders.

The oral JAK1 inhibitor povorcitinib elicits clinical response in the subpopulation of hidradenitis suppurativa (HS) patients who had prior treatment with anti-TNF, according to pooled 24-week data from the phase III STOP-HS trials.

Once-daily application of roflumilast cream 0.3% is associated with a significantly higher rate of treatment success on the Investigator's Global Assessment (IGA) scale in Chinese patients with plaque psoriasis compared with a vehicle cream, according to the phase III DERMIS-1 and -2 studies presented at AAD 2026.

Patients with psoriasis appear to have the lowest risk of developing psoriatic arthritis (PsA) when they are treated with IL-23 inhibitors than with other immunomodulatory agents, according to a real-world study.